A review of patient self-report tools for chemotherapy-induced nausea and vomiting
暂无分享,去创建一个
[1] S B Kaye,et al. On the receiving end--patient perception of the side-effects of cancer chemotherapy. , 1983, European journal of cancer & clinical oncology.
[2] M. Johnson,et al. Development of reliable and valid measures of nausea and vomiting , 1984, Cancer nursing.
[3] A McMurray,et al. Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] G. Morrow. Methodology in behavioral and psychosocial cancer research. The assessment of nausea and vomiting. Past problems, current issues and suggestions for future research. , 1984, Cancer.
[5] C. Presant. Quality of life in cancer patients. Who measures what? , 1984, American journal of clinical oncology.
[6] [Nausea and vomiting]. , 1987, Rivista dell'infermiere.
[7] P. Brantley,et al. Test-retest reliability and concurrent validity of the Morrow Assessment of Nausea and Emesis (MANE) for the assessment of cancer chemotherapy-related nausea and vomiting , 1988 .
[8] D. Streiner,et al. Health Measurement Scales: A practical guide to thier development and use , 1989 .
[9] C. L. M. Carnike, Jr.,et al. Assessing Nausea and Vomiting in Adult Chemotherapy Patients: Review and Recommendations , 1990 .
[10] G. Morrow. A patient report measure for the quantification of chemotherapy induced nausea and emesis: psychometric properties of the Morrow assessment of nausea and emesis (MANE). , 1992, The British journal of cancer. Supplement.
[11] D L Streiner,et al. A checklist for evaluating the usefulness of rating scales. , 1993, Canadian journal of psychiatry. Revue canadienne de psychiatrie.
[12] D. Osoba,et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.
[13] D. Osoba. Lessons learned from measuring health-related quality of life in oncology. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] J. Matthews,et al. The roles of patient and observer assessments in anti-emetic trials. , 1994, European journal of cancer.
[15] S. Madajewicz,et al. Efficacy and tolerability of oral ondansetron versus prochlorperazine in the prevention of emesis associated with cyclophosphamide-based chemotherapy and maintenance of health-related quality of life. , 1996, Clinical therapeutics.
[16] P. Butow,et al. On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] A. Kiltie,et al. Ondansetron versus a chlorpromazine and dexamethasone combination for the prevention of nausea and vomiting: a prospective, randomised study to assess efficacy, cost effectiveness and quality of life following single-fraction radiotherapy , 1997, Supportive Care in Cancer.
[18] M. Frank-Stromborg,et al. Instruments for clinical health-care research , 1997 .
[19] J. Verweij,et al. Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. , 1997, British Journal of Cancer.
[20] A. Depierre,et al. The efficacy of a combination of ondansetron, methyiprednisolone and metopimazine in patients previously uncontrolled with a dual antiemetic treatment in cisplatin-based chemotherapy , 1997 .
[21] D. Osoba,et al. Effect of postchemotherapy nausea and vomiting on health-related quality of life , 1997, Supportive Care in Cancer.
[22] K. Colgan,et al. Patients' self-reported functional status after granisetron or ondansetron therapy to prevent chemotherapy-induced nausea and vomiting at six cancer centers. , 1997, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[23] D. Osoba,et al. Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] M. Kris,et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] M. Tonato,et al. Methodology of antiemetic trials: response assessment, evaluation of new agents and definition of chemotherapy emetogenicity , 1998, Supportive Care in Cancer.
[26] Mail-in questionnaire for monitoring nausea and vomiting in oncology outpatients. , 1998, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[27] S. McMillan,et al. Quality of life in cancer patients: use of a revised Hospice Index. , 1998, Cancer Practice.
[28] L. Sarna. Effectiveness of structured nursing assessment of symptom distress in advanced lung cancer. , 1998, Oncology nursing forum.
[29] R. Stern,et al. Use of 5‐HT3 receptor antagonists to prevent nausea and emesis caused by chemotherapy for patients with breast carcinoma in community practice settings , 1999 .
[30] L. Hayman,et al. Parents associated with children in measuring acute and delayed nausea and vomiting. , 1999, Nursing & health sciences.
[31] R. McDaniel,et al. The Index of Nausea, Vomiting, and Retching: a new format of the lndex of Nausea and Vomiting. , 1999, Oncology nursing forum.
[32] Use of 5-HT3 receptor antagonists to prevent nausea and emesis caused by chemotherapy for patients with breast carcinoma in community practice settings. , 1999, Cancer.
[33] Kunihiko Kobayashi,et al. Effects of anti‐emetic drug (tropisetron) on quality of life during chemotherapy: Use of a diary‐type questionnaire and application of summary measures for assessment in a randomized, multicentre study , 1999, Respirology.
[34] R. Stern,et al. Nausea and vomiting remain a significant clinical problem: trends over time in controlling chemotherapy-induced nausea and vomiting in 1413 patients treated in community clinical practices. , 2000, Journal of pain and symptom management.
[35] J. Chapman,et al. Acupressure for nausea: results of a pilot study. , 2000, Oncology nursing forum.
[36] Ji-Young Kim,et al. The Index of Nausea, Vomiting, and Retching(Korean Translation) , 2000 .
[37] A. Molassiotis,et al. The effectiveness of progressive muscle relaxation training in managing chemotherapy-induced nausea and vomiting in Chinese breast cancer patients: a randomised controlled trial , 2002, Supportive Care in Cancer.
[38] [Development of a Japanese version of the FLIE]. , 2002, Gan to kagaku ryoho. Cancer & chemotherapy.
[39] M. Fu,et al. The Chinese Translation of the Index of Nausea, Vomiting, and Retching , 2002, Cancer nursing.
[40] J. Luce,et al. Delayed chemotherapy-induced nausea in women treated for breast cancer. , 2003, Oncology nursing forum.
[41] J. Pearson,et al. Assessing the impact of chemotherapy-induced nausea and vomiting on patients' daily lives: a modified version of the Functional Living Index—Emesis (FLIE) with 5-day recall , 2003, Supportive Care in Cancer.
[42] Charles G. Martin,et al. Measuring chemotherapy‐induced nausea and emesis , 2003, Cancer.
[43] J. Atkins,et al. Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5‐hydroxytryptamine‐3 antiemetics , 2003, Cancer.
[44] J. Pearson,et al. Functional relevance of antiemetic control. Experience using the FLIE questionnaire in a randomised study of the NK-1 antagonist aprepitant. , 2003, European journal of cancer.
[45] K. Horgan,et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy‐induced nausea and vomiting , 2003, Cancer.
[46] F. Roila,et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] N. Kearney,et al. Chemotherapy-related nausea and vomiting - past reflections, present practice and future management. , 2004, European journal of cancer care.
[48] A. Hüsler,et al. Chemotherapy-induced nausea and vomiting in routine practice: a European perspective , 2004, Supportive Care in Cancer.
[49] G. de Pouvourville,et al. Incidence of chemotherapy‐induced nausea and emesis after modern antiemetics , 2004, Cancer.
[50] M. Mori,et al. How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] Manfred Stommel,et al. Symptom clusters in elderly patients with lung cancer. , 2004, Oncology nursing forum.
[52] J. Osterhaus,et al. Quality of life consequences of chemotherapy-induced emesis , 1992, Quality of Life Research.
[53] Howard S. Smith,et al. A Receptor-Based Paradigm of Nausea and Vomiting , 2005 .
[54] N. Kearney,et al. Nursing Patients with Cancer. Principles and Practice. , 2005 .
[55] S. Kuo,et al. Assessing the Psychometric and Language Equivalency of the Chinese Versions of the Index of Nausea, Vomiting and Retching, and the Prenatal Self‐evaluation Questionnaire , 2005, The Kaohsiung journal of medical sciences.
[56] A. Molassiotis,et al. Nausea and vomiting , 2006 .
[57] L. Schwartzberg. Chemotherapy-induced nausea and vomiting: state of the art in 2006. , 2006, The journal of supportive oncology.
[58] E. Demeyer,et al. Measuring the maintenance of daily life activities using the functional living index-emesis (FLIE) in patients receiving moderately emetogenic chemotherapy. , 2006, The journal of supportive oncology.
[59] M. Huschka,et al. Does QOL provide the same information as toxicity data? , 2006, Current problems in cancer.
[60] K. Bergkvist,et al. Symptom experiences during chemotherapy treatment--with focus on nausea and vomiting. , 2006, European journal of oncology nursing : the official journal of European Oncology Nursing Society.
[61] A. Molassiotis,et al. A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre , 2008, Supportive Care in Cancer.
[62] A. Molassiotis,et al. The effects of P6 acupressure in the prophylaxis of chemotherapy-related nausea and vomiting in breast cancer patients. , 2007, Complementary therapies in medicine.
[63] S. Beck,et al. Treatment-related symptom clusters. , 2007, Seminars in oncology nursing.
[64] C. Clements,et al. Validation and psychometric assessment of a short clinical scale to measure chemotherapy-induced nausea and vomiting: the MASCC antiemesis tool. , 2007, Journal of pain and symptom management.
[65] E. Waclawski. Health Measurement Scales—A Practical Guide to Their Development and Use , 2010 .